Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032862 | 0.95 | SLC6A5 (0.66) | CNR1ALDH1A1HPGDSLC6A5TRPV1 | |
| SCHEMBL4392061 | 0.94 | SLC6A5 (0.71) | CNR1ALDH1A1HPGDSLC6A5TRPV1 | |
| SCHEMBL31378237 | 0.93 | CNR1 (0.70) | CNR1ALDH1A1HPGDSLC6A5TRPV1 | |
| SCHEMBL30571243 | 0.93 | CNR1 (0.70) | CNR1ALDH1A1HPGDSLC6A5TRPV1 | |
| SCHEMBL10028552 | 0.93 | SLC6A5 (0.69) | CNR1ALDH1A1HPGDSLC6A5TRPV1 | |
| SCHEMBL25835296 | 0.89 | SLC6A5 (0.54) | CNR1SLC6A5 | |
| SCHEMBL25835310 | 0.89 | SLC6A5 (0.54) | CNR1SLC6A5 | |
| SCHEMBL25835398 | 0.88 | CNR1 (0.67) | CNR1ALDH1A1HPGDTRPV1MEN1 | |
| SCHEMBL25067294 | 0.87 | SLC6A5 (0.52) | SLC6A5 | |
| SCHEMBL25067425 | 0.87 | SLC6A5 (0.52) | SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226193-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | CPT1B, MUSK, MYLK2 | CNR1 4510/4885ALDH1A1 1330/4885HPGD 2974/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.